Related Experiment Video
Updated: May 9, 2026
06:47
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
Published on: January 28, 2021
Focus on lipoprotein(a).
Marta Biolo1, Camilla Portinari1, Camilla Goffi1
1Clinica Medica 1, Department of Medicine, University Hospital-Padua, Via Giustiniani 2, Padua 35128, Italy.
Summary
Elevated Lipoprotein(a) [Lp(a)] is a key cardiovascular risk factor. Current management focuses on lowering LDL cholesterol, while novel therapies targeting Lp(a) show promising reductions.
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Lipoprotein(a) [Lp(a)] is a significant, independent risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis.
- Elevated Lp(a) affects approximately 20% of the population, with levels primarily determined by genetic variations in the LPA gene.
Purpose of the Study:
- To review the role of Lp(a) as a cardiovascular risk factor.
- To discuss current management strategies for elevated Lp(a).
- To explore emerging therapeutic approaches for Lp(a) reduction.
Main Methods:
- Review of current clinical guidelines and therapeutic strategies for managing elevated Lp(a).
- Examination of the genetic basis of Lp(a) regulation.
- Assessment of novel Lp(a)-lowering therapies in development.
Main Results:
- Lp(a) possesses enhanced atherogenic, pro-inflammatory, and prothrombotic properties compared to LDL.
- Current guidelines recommend intensive LDL cholesterol lowering to manage residual risk from Lp(a).
- Lipoprotein apheresis offers substantial Lp(a) reduction but has limited applicability.
Conclusions:
- Innovative therapies, including gene silencing and assembly inhibitors, demonstrate significant Lp(a) reduction (up to 80-90%).
- These novel approaches offer potential for causal therapeutic strategies pending cardiovascular outcome trial results.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:24Lipid Absorption
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...